Teva Pharmaceuticals USA Inc. has voluntarily recalled 4,224 cartons of Anagrelide Capsules USP, 0.5 mg. The recall was issued because the medication failed dissolution stability testing, which means the capsules may not break down properly in the body as intended. No incidents or injuries have been reported in connection with this issue. The prescription medication is sold in 100-count bottles and was distributed to pharmacies nationwide.
If the capsules do not dissolve correctly, the medication may not be fully absorbed by the body. This could lead to the drug being less effective at treating conditions related to high platelet counts.
You have 2 options:
Quantity: 4224 cartons
Product Labeling, Anagrelide Capsules USP, 0.5 mg
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.